These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21555125)

  • 1. Ng YH, Gino PD, Lingaraj K, Das De S. Femoral shaft fracture in the elderly - role of prior bisphosphonate therapy.
    Haque S; Siddiqui G
    Injury; 2012 Jul; 43(7):1221. PubMed ID: 21555125
    [No Abstract]   [Full Text] [Related]  

  • 2. Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.
    Ng YH; Gino PD; Lingaraj K; Das De S
    Injury; 2011 Jul; 42(7):702-6. PubMed ID: 21316051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous femoral shaft fracture after long-term alendronate.
    Ali T; Jay RH
    Age Ageing; 2009 Sep; 38(5):625-6. PubMed ID: 19556326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atraumatic bilateral femur fracture in long-term bisphosphonate use.
    Ott SM
    Orthopedics; 2010 Jul; 33(7):468. PubMed ID: 20608597
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical femoral fractures: a complication of prolonged bisphosphonate therapy?
    Falkenberg MP
    Med J Aust; 2011 Jan; 194(2):102-3; author reply 103. PubMed ID: 21241227
    [No Abstract]   [Full Text] [Related]  

  • 6. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Femoral canal obliteration secondary to prolonged alendronate use: a case report.
    Lim CT; Setiobudi T; Das De S
    J Orthop Surg (Hong Kong); 2012 Apr; 20(1):115-7. PubMed ID: 22535826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
    Kharazmi M; Hallberg P; Warfvinge G; Michaëlsson K
    Rheumatology (Oxford); 2014 Oct; 53(10):1911-3. PubMed ID: 25099769
    [No Abstract]   [Full Text] [Related]  

  • 9. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
    Capeci CM; Tejwani NC
    J Bone Joint Surg Am; 2009 Nov; 91(11):2556-61. PubMed ID: 19884427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
    Osugi K; Miwa S; Marukawa S; Marukawa K; Kawaguchi Y; Nakato S
    Acta Orthop; 2011 Feb; 82(1):112-3. PubMed ID: 21142824
    [No Abstract]   [Full Text] [Related]  

  • 11. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.
    Lenart BA; Lorich DG; Lane JM
    N Engl J Med; 2008 Mar; 358(12):1304-6. PubMed ID: 18354114
    [No Abstract]   [Full Text] [Related]  

  • 12. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
    Lee JK
    Int J Rheum Dis; 2009 Jul; 12(2):149-54. PubMed ID: 20374333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature.
    Agarwal S; Agarwal S; Gupta P; Agarwal PK; Agarwal G; Bansal A
    Acta Orthop Belg; 2010 Oct; 76(5):567-71. PubMed ID: 21138208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
    Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
    Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?
    Edwards MH; McCrae FC; Young-Min SA
    Osteoporos Int; 2010 Apr; 21(4):701-3. PubMed ID: 19562241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical femoral fracture after long-term alendronate treatment: report of a case evidenced with magnetic resonance imaging.
    Kao CM; Huang PJ; Chen CH; Chen SJ; Cheng YM
    Kaohsiung J Med Sci; 2012 Oct; 28(10):555-8. PubMed ID: 23089322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.